A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

類似資料

• The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome
  著者:: McDermott, David H., 等
  出版事項: (2011)
• AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome
  著者:: McDermott, David H, 等
  出版事項: (2011)
• Plerixafor for the Treatment of WHIM Syndrome
  著者:: McDermott, David H., 等
  出版事項: (2019)
• Chromothriptic Cure of WHIM Syndrome
  著者:: McDermott, David H., 等
  出版事項: (2015)
• The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome
  著者:: Dale, David C., 等
  出版事項: (2011)